Solute Carrier Transporters as Potential Targets for the Treatment of Metabolic Disease
Parhofer et al. 2019 – ExpClin Endocrinol Diabetes
Position Paper on Lipid Therapy in Patients with Diabetes Mellitus.
New insight into the mechanisms of ectopic fat deposition improvement after bariatric surgery.
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
Are Lifestyle Therapies Effective for NAFLD Treatment?
Status of hypertension in Europe.
Analysis of naturally occurring mutations in the human uptake transporter NaCT important for bone and brain development and energy metabolism.
Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk: Implications for Hypertension Management.
Review: The longevity gene INDY (I’m Not Dead Yet) in metabolic control: Potential as pharmacological target
The Human Longevity Gene Homolog INDY and Interleukin-6 Interact in Hepatic Lipid Metabolism
Inhibition of citrate cotransporter Slc13a5/mINDY by RNAi improves hepatic insulin sensitivity and prevents diet-induced non-alcoholic fatty liver disease in mice
The longevity transporter mIndy (Slc13a5) as a target for treating hepatic steatosis and insulin resistance
Cardiometabolic crosstalk in obesity-associated arterial hypertension
Joint scientific statement of the European Association for the Study of Obesity and the European Society of Hypertension: Obesity and early vascular ageing.
Arylhydrocarbon receptor (AhR) dependent mIndy (Slc13a5) induction as possible contributor to benzo[a]pyrene induced lipid accumulation in hepatocytes
Knockdown of Indy/CeNac2 extends Caenorhabditis elegans life span by inducing AMPK/aak‐2.
Prevention of diet‐induced hepatic steatosis and hepatic insulin resistance by second generation antisense oligonucleotides targeted to the longevity gene mIndy (Slc13a5).
The Mammalian INDY Homolog is Induced by cAMP responsive-element-binding protein (CREB) in a Rat Model of Type 2 Diabetes.
The Role of INDY in Metabolic Regulation (Review)
Deletion of the Mammalian INDY Homolog Mimics Aspects of Dietary Restriction and Protects against Adiposity and Insulin Resistance in Mice.
Combination of Mitochondrial and Plasma Membrane Citrate Transporter Inhibitors Inhibits De Novo Lipogenesis Pathway and Triggers Apoptosis in Hepatocellular Carcinoma Cells.
Suppressed de novo lipogenesis by plasma membrane citrate transporter inhibitor promotes apoptosis in HepG2 cells.
Flipping a citrate switch on liver cancer cells.
Silencing of solute carrier family 13 member 5 disrupts energy homeostasis and inhibits proliferation of human hepatocarcinoma cells
INDY-A New Link to Metabolic Regulation in Animals and Humans
Molecular Basis for Inhibition of the Na+/Citrate Transporter NaCT (SLC13A5) by Dicarboxylate Inhibitors
State-Dependent Allosteric Inhibition of the Human SLC13A5 Citrate Transporter by Hydroxysuccinic Acids, PF-06649298 and PF-06761281
Optimization of a Dicarboxylic Series for in Vivo Inhibition of Citrate Transport by the Solute Carrier 13 (SLC13) Family
Discovery and characterization of novel inhibitors of the sodium-coupled citrate transporter (NaCT or SLC13A5)
Recessive mutations in SLC13A5 result in a loss of citrate transport and cause neonatal epilepsy, developmental delay and teeth hypoplasia
Species-specific Influence of Lithium on the Activity of SLC13A5 (NaCT): Lithium-induced Activation is Specific for the Transporter in Primates.
Structure and mechanism of a bacterial sodium-dependent dicarboxylate transporter (crystal structure of vcINDY, a bacterial homologue of INDY, NaCT).
Expression and functional features of NaCT, a sodium-coupled citrate transporter, in human and rat livers and cell lines.
Human Na+-coupled citrate transporter (NaCT): primary structure, genomic organization, and transport function.
Extended Life-Span Conferred by Cotransporter Gene Mutations in Drosophila (discovery of INDY: I am Not Dead Yet).